initial-assessment-memo.docx

1018-00009 · Client 1018 · Strategy

initial-assessment-memo.docx DOCUMENT M&A / Corporate

158 / 176 ← → ✕

MEMORANDUM

TO: Marcus Whitfield, Vice President, Global Tax, Penterra Pharmaceuticals Corp. Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp.

FROM: Leonard Cross, Partner, Calderwood & Harkness LLP Garrett Simmons, Associate, Calderwood & Harkness LLP

DATE: June 15, 2022

RE: Preliminary Assessment — IRS Large Business & International Division Examination of Penterra Pharmaceuticals Corp. Transfer Pricing (Tax Years 2017–2020)

C&H Matter No.: 1018-00009

Right-click to update Table of Contents

I. Executive Summary

Calderwood & Harkness LLP ("C&H") was retained on June 2, 2022, to represent Penterra Pharmaceuticals Corp. ("PPC" or the "Company") in connection with an examination opened by the Internal Revenue Service Large Business & International Division ("LB&I") on May 16, 2022. The examination was initiated by Letter 2205-A and has been assigned Exam Team ID LB&I-NE-TP-2022-00641. The examination covers PPC's consolidated federal income tax returns (Forms 1120) for Tax Years 2017, 2018, 2019, and 2020.

Based on our review of the initial contact letter, the composition of the IRS examination team, and our preliminary analysis of PPC's intercompany arrangements, the examination is focused on PPC's transfer pricing arrangements with its Irish subsidiary, Penterra Biopharma International DAC ("PBI"). Specifically, we believe the IRS will concentrate its inquiry on three core areas: (a) the cost-sharing arrangement ("CSA") between PPC and PBI, including the reasonably anticipated benefits ("RAB") methodology used to allocate qualified R&D costs; (b) the legacy IP royalty arrangement under which PBI licenses pre-2012 compounds from PPC for non-Americas commercialization at a royalty rate of 4.5% of net sales; and (c) the 2012 platform contribution transaction ("PCT") under which PBI made a lump-sum payment of $312 million to PPC as consideration for a buy-in to pre-existing pharmaceutical intellectual property.

On June 8, 2022, IRS Form 2848 (Power of Attorney and Declaration of Representative) was filed with the Internal Revenue Service authorizing Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari, all of Calderwood & Harkness LLP, to represent PPC before the IRS in connection with this examination for Tax Years 2017 through 2020.

This memorandum provides our initial assessment of: (a) the scope and posture of the examination, including the composition and likely approach of the IRS examination team; (b) PPC's current transfer pricing positions and their defensibility under applicable Treasury Regulations, case law, and OECD Transfer Pricing Guidelines; (c) potential exposure areas and a preliminary quantification of the financial risk to PPC, including tax, penalty, and interest implications; and (d) recommended next steps for organizing and executing PPC's defense.

We note that PPC was not enrolled in the IRS Compliance Assurance Process ("CAP") for any of the tax years at issue, and accordingly there has been no prior interaction with the IRS regarding the transfer pricing positions now under examination. This is the first comprehensive IRS examination of PPC's international tax structure since the CSA was entered into in 2012.

Overall Assessment: Based on our preliminary review, PPC's transfer pricing positions are well-documented and defensible, supported by contemporaneous transfer pricing reports prepared by Crestfield & Associates LLP ("Crestfield") and grounded in methodologies prescribed by the applicable Treasury Regulations. However, certain areas — most notably the legacy IP royalty rate and the projection-dependent RAB cost-sharing percentages — present moderate risk and will require focused preparation and, potentially, supplemental economic analysis. We have engaged Whitmore Valuation Group LLC ("Whitmore") under a Kovel arrangement to provide independent economic analysis in support of the defense. The sections that follow set forth our detailed findings and recommendations.

II. Background — PPC's Corporate Structure and IP Arrangements

A. Corporate Structure Overview

Penterra Pharmaceuticals Corp. is a corporation organized under the laws of the State of Delaware and publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. PPC's principal executive offices are located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company whose therapeutic focus areas include oncology, immunology, and rare-disease therapeutics.

For the fiscal year ended December 31, 2020, PPC reported consolidated global revenue of approximately $6.82 billion, consolidated pre-tax income of approximately $1.47 billion, and employed approximately 14,500 individuals globally across its U.S. headquarters, research and development facilities, and international subsidiaries and affiliates.

PPC's senior management team during the examination period included Catherine Falk as Chief Executive Officer, Rajesh Iyer as Chief Financial Officer, Deborah Staines as General Counsel, and Marcus Whitfield as Vice President, Global Tax.

PPC's international corporate structure relevant to this examination is organized as follows:

• Penterra Pharmaceuticals Corp. ("PPC") — Delaware corporation; ultimate U.S. parent entity; headquartered at 2200 Independence Boulevard, Princeton Junction, NJ 08550.

• Penterra Holdings Luxembourg S.à r.l. ("PHL") — A société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg; registered at 14, rue Aldringen, L-1118 Luxembourg; Luxembourg Registre de Commerce et des Sociétés ("RCS") No. B 168452. PHL is wholly owned by PPC and is treated as a disregarded entity for U.S. federal income tax purposes. PHL serves as an intermediate holding company for PPC's European operations.

• Penterra Biopharma International DAC ("PBI") — A Designated Activity Company organized under Irish law; registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland; Irish Companies Registration Office ("CRO") No. 489216; Irish Tax Reference No. 3218764T. PBI is wholly owned by PHL. PBI serves as the intellectual property holding company and commercial principal for PPC's non-Americas territories. Aidan Naughton serves as Managing Director. As of December 31, 2020, PBI employed 185 individuals, a significant increase from the 52 employees at the time of PBI's incorporation in March 2012.

• Penterra Manufacturing Ireland Ltd. ("PMI") — An Irish limited company; registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland; Irish CRO No. 512347. PMI is wholly owned by PBI and operates as a contract manufacturer of PPC's oncology and immunology biologic products for non-Americas markets. PMI operates under a cost-plus transfer pricing arrangement with PBI, receiving cost plus an 8% markup for manufacturing services. PMI employs approximately 620 individuals at its Ringaskiddy facility.

This corporate structure has been in place since 2012, when PBI was incorporated and the cost-sharing arrangement was entered into. The structure was designed to centralize PPC's non-Americas intellectual property ownership and commercialization functions in Ireland, leveraging Ireland's favorable corporate tax regime (12.5% on trading income) and the availability of Ireland's Knowledge Development box ("KDB") regime (effective rate of 6.25% on qualifying IP income), which PBI has claimed from fiscal year 2016 forward.

B. The Cost-Sharing Arrangement

PBI was incorporated on March 15, 2012. Effective July 1, 2012, PPC and PBI entered into a qualified Cost-Sharing Arrangement (the "CSA") pursuant to which PBI acquired the right to develop and exploit PPC's pharmaceutical IP portfolio outside the Americas region. For purposes of the CSA, the "Americas" territory is defined to include North America (the United States, Canada, and Mexico), Central America, South America, and the Caribbean. All other territories — including Europe, the Middle East, Africa, and Asia-Pacific — constitute PBI's territory under the CSA.

The CSA was structured in accordance with the requirements of Treasury Regulation § 1.482-7, governing qualified cost-sharing arrangements. As consideration for PBI's buy-in to the pre-existing intellectual property contributed by PPC to the CSA, PBI made a lump-sum platform contribution transaction payment of $312 million to PPC on July 1, 2012. The pre-existing IP contributed by PPC consisted primarily of clinical-stage and approved oncology compounds, including the precursor formulations and clinical data packages for what would become PPC's blockbuster oncology product, Veritaxol.

Under the ongoing terms of the CSA, PBI makes cost-sharing payments to PPC on an annual basis, proportional to PBI's reasonably anticipated benefits from the intangible development activities funded by the CSA. The RAB methodology is based on projected revenue splits between the Americas territory (PPC's area) and the non-Americas territory (PBI's area), applied to the total qualified R&D cost pool.

PBI's share of annual qualified R&D costs during the examination years was as follows:

The progressive increase in PBI's cost-sharing percentage — from 38.2% in Tax Year 2017 to 42.7% in Tax Year 2020 — reflects the organic growth of PPC's non-Americas business, driven primarily by the successful commercialization of Veritaxol and Imvara in European and Asia-Pacific markets during this period. These percentages were recalculated each year based on updated revenue projections for each territory, as prescribed by the CSA agreement and consistent with the methodology documented in Crestfield's contemporaneous transfer pricing reports.

C. The Legacy IP Royalty Arrangement

Separately from and in addition to the CSA, PBI licenses certain legacy pharmaceutical compounds from PPC under a license agreement entered into contemporaneously with the CSA. The legacy compounds consist of pre-2012 vintage products that were not included within the scope of the CSA's intangible development activities but for which PBI was granted exclusive commercialization rights in the non-Americas territory.

Under this license agreement, PBI pays PPC a royalty of 4.5% of net sales for the non-Americas territory. The royalty rate was established based on a comparable uncontrolled transaction ("CUT") analysis performed by Crestfield at the time the license was entered into. The arrangement was structured in accordance with Treasury Regulation § 1.482-4, which sets forth methods to determine the arm's-length consideration for the transfer of intangible property.

Legacy compound non-Americas net sales and corresponding royalty payments during the examination years were as follows:

The declining trajectory in legacy compound net sales reflects the natural lifecycle of the pre-2012 product portfolio, as these compounds have progressively lost market share to newer products developed under the CSA. The total royalty income received by PPC from the legacy license over the four-year examination period was approximately $130.17 million.

D. Key Products

PPC's product portfolio includes three major therapeutic products that account for the substantial majority of its global revenue:

Veritaxol (Oncology). Veritaxol is PPC's blockbuster oncology product, a monoclonal antibody therapy indicated for the treatment of non-small cell lung cancer and certain other solid tumors. Veritaxol was approved by the U.S. Food and Drug Administration in 2014 and has subsequently received regulatory approval in over 60 countries worldwide. For fiscal year 2020, Veritaxol generated global net sales of approximately $3.12 billion, of which approximately $1.34 billion (approximately 43% of global sales) was attributable to non-Americas markets within PBI's territory.

Imvara (Immunology). Imvara is PPC's leading immunology product, indicated for the treatment of moderate-to-severe rheumatoid arthritis and psoriatic arthritis. Imvara received FDA approval in 2016 and has been commercially launched in approximately 45 countries. For fiscal year 2020, Imvara generated global net sales of approximately $1.87 billion, of which approximately $0.79 billion (approximately 42% of global sales) was attributable to non-Americas markets.

Cerulon (Rare Disease). Cerulon is an enzyme replacement therapy for the treatment of a rare lysosomal storage disorder. Cerulon received FDA approval in 2013 and has obtained orphan drug designation in several jurisdictions. For fiscal year 2020, Cerulon generated global net sales of approximately $0.62 billion, of which approximately $0.28 billion (approximately 45% of global sales) was attributable to non-Americas markets.

The geographic distribution of revenues for these products is a critical input to the RAB methodology used in the CSA, and any IRS challenge to the cost-sharing percentages will necessarily involve a detailed examination of the revenue allocation between PPC's Americas territory and PBI's non-Americas territory for each product line.

E. PBI's Functions, Assets, and Risks

A thorough understanding of PBI's operations in Ireland is essential to PPC's defense, particularly with respect to any IRS challenge to PBI's economic substance and DEMPE functions. Based on our preliminary review of PPC's transfer pricing documentation and our initial discussions with PPC management, PBI's operational profile is as follows:

Functions. PBI functions as the intellectual property holding company and commercial principal for all of PPC's non-Americas operations. PBI manages contract manufacturing arrangements with PMI (and, for certain products, with third-party contract manufacturers in Germany and Singapore), oversees distribution arrangements across 68 country markets in the EMEA and Asia-Pacific regions, and bears primary responsibility for regulatory, medical-affairs, commercial-strategy, and supply-chain functions in the non-Americas territory. PBI maintains a team of experienced pharmaceutical professionals in Dublin who perform the following key functions:

• Regulatory affairs: PBI's regulatory team manages all regulatory submissions, market authorization applications, and post-approval commitments for non-Americas markets, including submissions to the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency, and over 50 national regulatory authorities. During the 2017–2020 period, PBI incurred cumulative regulatory expenditures of approximately €47.2 million on these submissions and related activities.

• Medical affairs: PBI employs medical science liaisons and medical directors responsible for post-marketing surveillance, pharmacovigilance reporting, medical information, and medical education programs in the non-Americas territory.

• Commercial strategy: PBI makes key commercial decisions including product pricing, market entry sequencing, distribution partner selection and management, and promotional strategy across its 68 country markets. These decisions are made by PBI's commercial leadership team in Dublin, subject to oversight by PBI's board of directors.

• Supply chain management: PBI manages the supply chain for non-Americas markets, coordinating with PMI and third-party contract manufacturers to ensure product availability, inventory management, and quality control.

Assets. PBI holds the rights to PPC's pharmaceutical IP for the non-Americas territory under the CSA, as well as the licensed rights to legacy compounds under the royalty arrangement. PBI also holds intangible assets in the form of regulatory dossiers, market authorizations, and distribution agreements in non-Americas markets. PBI maintains approximately 18,000 square feet of office space at Sandyford Business Park in Dublin.

Risks. PBI bears significant market risk for non-Americas territories, including pricing risk, competitive risk, regulatory risk, and foreign currency risk. PBI is responsible for commercial outcomes in its territory and absorbs losses in the event of adverse market developments, regulatory setbacks, or competitive pressures. PBI also bears the risk associated with its share of R&D costs under the CSA, as there is no guarantee that the R&D activities funded through the CSA will result in commercially viable products.

Governance. PBI's board of directors met 42 times during the 2017–2020 period — approximately quarterly plus additional special sessions convened to address significant commercial, regulatory, and strategic matters. All board meetings were held in Dublin. The board's meeting minutes reflect substantive deliberation on key commercial decisions, including pricing strategies, market entry decisions, and responses to competitive developments in non-Americas markets.

Financial Profile. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI's Irish effective tax rate on trading income was 12.5%, and PBI claimed benefits under Ireland's Knowledge Development box at an effective rate of 6.25% on qualifying IP income from fiscal year 2016 forward. PBI maintains its primary banking relationship with Glenmore Bank Ireland plc and manages its treasury functions locally in Dublin.

Irish Tax Advisory. PBI's Irish tax compliance and advisory services are provided by Thornbury & Keogh, Chartered Tax Advisors, Dublin (Lead Partner: Ciarán Thornbury; 22 Fitzwilliam Square, Dublin 2, D02 YH68, Ireland). Thornbury & Keogh has advised PBI since its incorporation in 2012 and has been instrumental in securing PBI's Knowledge Development box benefits and managing PBI's relationship with the Irish Revenue Commissioners.

F. Contemporaneous Transfer Pricing Documentation

PPC's contemporaneous transfer pricing documentation for all four tax years under examination (2017–2020) was prepared by Crestfield & Associates LLP ("Crestfield"). The engagement was led by Martin Ogilvy, CPA (Engagement Partner) and Susan Lam, CPA (Transfer Pricing Partner). Crestfield is located at 1200 Avenue of the Americas, New York, NY 10036.

The transfer pricing documentation was prepared in accordance with the penalty-protection standards of IRC § 6662(e) and follows the methodologies prescribed in Treasury Regulations §§ 1.482-4 and 1.482-7. The documentation includes, among other things, (a) a description of PPC's organizational structure and business operations; (b) a functional analysis of PPC and PBI; (c) a description of the CSA, including the RAB methodology and the annual cost-sharing calculations; (d) a description of the legacy IP royalty arrangement, including the CUT analysis supporting the 4.5% royalty rate; (e) the selection and application of the best method under the regulations; and (f) the economic analyses supporting PPC's transfer pricing positions.

C&H is coordinating with Crestfield for access to all return data, workpapers, and underlying analyses related to the four examination years. We have made an initial request to Susan Lam for a complete set of transfer pricing documentation, and we anticipate receiving the first production by early July 2022.

III. Scope and Posture of the IRS Examination

A. Examination Opening and Team

The IRS opened the examination by issuing Letter 2205-A, dated May 16, 2022, notifying PPC that its consolidated federal income tax returns for Tax Years 2017, 2018, 2019, and 2020 had been selected for examination. The examination has been assigned to the LB&I Northeast Transfer Pricing Practice, with Team ID LB&I-NE-TP-2022-00641.

The IRS examination team is composed of the following individuals, as identified in the initial contact letter and subsequent communications:

• Supervisory Revenue Agent / Team Manager: Gerald Meskill. Mr. Meskill will serve as the team manager for the examination, overseeing all aspects of the audit and serving as the primary decision-maker on the IRS side regarding the scope and direction of the examination.

• Lead Revenue Agent: Patricia Dunleavy. Ms. Dunleavy will serve as the day-to-day point of contact for the examination, issuing Information Document Requests, conducting interviews, and coordinating the IRS's factual investigation.

• IRS Economist: Dr. Alan Washburne, IRS Transfer Pricing Practice. Dr. Washburne is an economist within the IRS's Transfer Pricing Practice and will be responsible for conducting an independent economic analysis of PPC's transfer pricing positions, including benchmarking, valuation, and assessment of PPC's methodologies.

• IRS Office of Chief Counsel Attorney-Advisor: Franklin Rosario. Mr. Rosario will provide legal advice to the examination team on substantive tax law issues, including the application of IRC § 482, the Treasury Regulations governing cost-sharing arrangements, and relevant case law.

• IRS Office of Chief Counsel Senior Counsel: Donna Hirabayashi. Ms. Hirabayashi's involvement as senior counsel suggests that the Office of Chief Counsel is providing heightened oversight to this examination, which is consistent with an examination that the IRS views as having potential for significant proposed adjustments and possible litigation.

The composition of the IRS examination team is itself highly informative. The assignment of both an IRS economist (Dr. Washburne) and two Chief Counsel attorneys (Rosario and Hirabayashi) at the outset of the examination — rather than at a later stage after proposed adjustments have been developed — is a strong signal that the IRS views this as a significant examination that is likely to result in substantial proposed adjustments. In our experience with similar LB&I transfer pricing examinations of pharmaceutical companies, the early involvement of Chief Counsel is typically associated with examinations where the IRS intends to pursue formal adjustments and is prepared for potential litigation if the case cannot be resolved at exam level or through IRS Appeals.

B. Anticipated IRS Focus Areas

Based on the initial contact letter, the composition of the IRS examination team, and C&H's extensive experience with similar LB&I transfer pricing examinations of pharmaceutical and life sciences companies, we anticipate that the IRS will focus its inquiry on four primary areas:

1. PCT Valuation. The IRS is likely to scrutinize whether the $312 million PCT payment made by PBI to PPC on July 1, 2012, adequately compensated PPC for the pre-existing intellectual property transferred to PBI at the inception of the CSA. Although Tax Year 2012 is beyond the four-year examination window, the IRS may use any perceived PCT undervaluation as a basis for challenging the ongoing CSA economics during the 2017–2020 period. Specifically, the IRS may argue that an understated PCT payment distorts the CSA by allowing PBI to retain a disproportionate share of residual returns from the exploitation of the contributed IP. In recent LB&I examinations, the IRS has employed this approach to link PCT valuation disputes to adjustments in subsequent tax years, even when the PCT year itself is closed.

2. CSA Cost-Sharing Ratios. The IRS is likely to challenge whether PBI's cost-sharing percentages (38.2% in 2017 rising to 42.7% in 2020) accurately reflect PBI's reasonably anticipated benefits from the intangible development activities funded by the CSA. The IRS may argue that PPC's RAB projections overstate PBI's anticipated share of benefits and correspondingly understate PPC's share, resulting in an allocation of R&D costs that is not commensurate with income. The IRS may propose alternative allocation keys — such as operating profits rather than revenue — or may challenge the revenue projections themselves as insufficiently supportive of PBI's increasing cost-sharing percentages.

3. Legacy IP Royalty Rate. The IRS is likely to challenge whether the 4.5% royalty rate on legacy compound non-Americas net sales represents arm's-length compensation for the use of PPC's intangible property. In recent transfer pricing examinations of pharmaceutical companies, the IRS has consistently asserted that royalty rates in the range of 4%–5% substantially understate the arm's-length rate for pharmaceutical IP of this nature. The IRS may conduct its own CUT analysis using third-party pharmaceutical licensing agreements to support a significantly higher royalty rate.

4. PBI Economic Substance / DEMPE Functions. The IRS may challenge whether PBI has sufficient economic substance and performs adequate Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions to justify its role as the IP-holding company and CSA participant for the non-Americas territory. If the IRS can establish that critical development and enhancement functions — particularly core R&D, clinical trials management, and strategic IP portfolio decisions — remained in the United States under PPC's control, this would undermine the premise that PBI is entitled to the residual returns it currently earns from non-Americas exploitation. This argument, if successful, would provide support for both the CSA and royalty adjustments by recharacterizing PBI as a limited-function entity.

These four areas are interconnected, and the IRS is likely to pursue them as a coordinated theory: that PBI was undercharged for the initial IP buy-in (PCT), pays too little in ongoing cost-sharing (CSA), pays too little for legacy IP (royalties), and in any event lacks the substance to justify its current returns (DEMPE). PPC's defense must address each of these areas both individually and as part of a coherent overall narrative.

C. Expected Examination Process

Based on C&H's experience with LB&I transfer pricing examinations of comparable scope and complexity, we anticipate the following examination process:

IDR Phase (June 2022 through mid-to-late 2023). The IRS will issue a series of Information Document Requests seeking production of documents and data related to PPC's transfer pricing positions. We anticipate a minimum of 30–50 IDRs covering a wide range of topics, including the CSA agreement and amendments, the legacy license agreement, Crestfield's transfer pricing documentation and workpapers, R&D cost pool composition, revenue projections, PBI board minutes, organizational charts, personnel lists, intercompany agreements, and financial statements for PPC, PBI, and PMI. This phase is likely to span 12–18 months, during which the IRS will also conduct interviews of PPC and PBI personnel.

IRS Economic Analysis (Parallel Track). During the IDR phase, Dr. Washburne will conduct an independent economic analysis of PPC's transfer pricing arrangements. This analysis will likely include benchmarking studies identifying comparable companies and transactions, independent CUT analyses for the royalty rate, and a re-valuation of the PCT using the IRS's own assumptions regarding discount rates, revenue projections, and growth rates. The IRS economist's analysis will form the foundation for any proposed adjustments.

NOPA and 30-Day Letter (Anticipated late 2023). Following the IDR phase and the completion of the IRS's economic analysis, we expect the IRS to issue a Notice of Proposed Adjustment ("NOPA") setting forth the IRS's proposed transfer pricing adjustments, the legal and factual basis for each adjustment, and the proposed additional tax, penalties, and interest. The NOPA will be accompanied by a 30-Day Letter providing PPC the opportunity to file a formal Protest and request consideration by the IRS Independent Office of Appeals.

Appeals Phase (Anticipated 2024). If PPC disagrees with the proposed adjustments, we would recommend filing a formal Protest and seeking resolution through IRS Appeals. The Appeals process offers a significant opportunity for resolution, as Appeals Officers are authorized to consider the "hazards of litigation" in determining whether and on what terms to settle a case. In our experience, a substantial majority of transfer pricing cases in the pharmaceutical sector are resolved at Appeals without the need for litigation.

The early involvement of Chief Counsel (Rosario and Hirabayashi) suggests that the IRS may also be preparing for potential litigation in the U.S. Tax Court or the Court of Federal Claims in the event that the case cannot be resolved at exam level or through Appeals. While we believe litigation is unlikely given the defensibility of PPC's positions, PPC should be prepared for this contingency.

IV. Assessment of PPC's Transfer Pricing Positions

A. Cost-Sharing Arrangement — Cost-Sharing Ratios

1. PPC's Position

PPC's position is that PBI's cost-sharing percentages are based on a reasonable and consistently applied methodology for measuring PBI's reasonably anticipated benefits from the intangible development activities funded by the CSA. The RAB methodology employed by PPC uses projected revenue splits between the Americas territory (PPC's area) and the non-Americas territory (PBI's area) as the allocation key, consistent with the guidance set forth in Treasury Regulation § 1.482-7(e)(1), which provides that reasonably anticipated benefits are to be "measured on a basis that is consistent with the measurement of anticipated benefits used to determine the participants' cost sharing payments."

The RAB methodology has been consistently applied since the inception of the CSA in July 2012. Each year, PPC updates the revenue projections for each territory based on then-current market data, product lifecycle analysis, and commercial forecasts, and recalculates PBI's cost-sharing percentage accordingly. The progressive increase in PBI's cost-sharing percentage — from 38.2% in 2017 to 42.7% in 2020 — reflects the organic growth in PPC's non-Americas markets, particularly the strong uptake of Veritaxol in European and Asia-Pacific markets and the successful commercial launch of Imvara in those markets during this period.

The RAB methodology and the annual cost-sharing calculations are fully documented in Crestfield's contemporaneous transfer pricing reports for each tax year. These reports include detailed descriptions of the revenue projection methodology, the data sources used, the allocation calculations, and the resulting cost-sharing payments. The documentation was prepared in accordance with the penalty-protection standards of IRC § 6662(e) and satisfies the contemporaneous documentation requirements of Treasury Regulation § 1.482-7(k).

2. Potential IRS Challenge

We anticipate that the IRS will challenge PPC's RAB methodology and the resulting cost-sharing percentages on one or more of the following grounds:

(a) Revenue Projections. The IRS may argue that PPC's revenue projections for the non-Americas territory were overstated, resulting in an inflated RAB percentage for PBI and correspondingly understated cost-sharing payments. The IRS may point to differences between PPC's projections and actual results, or may substitute its own revenue projections based on different assumptions regarding market growth, pricing trends, or competitive dynamics.

(b) Allocation Key. The IRS may argue that revenue is not the most appropriate basis for measuring reasonably anticipated benefits, and may propose an alternative allocation key — such as operating profits or units sold — that would result in a different (likely lower) RAB percentage for PBI and a correspondingly higher cost-sharing burden.

(c) Intangible Development Activities. The IRS may assert that certain intangible development activities ("IDAs") funded through the CSA were disproportionately performed by PPC personnel in the United States, and that PBI's cost-sharing percentage should be adjusted to account for the fact that the U.S. R&D team performed a greater share of the value-creating work. This argument may be linked to the DEMPE challenge discussed in Section IV.D below.

Based on precedent in similar LB&I examinations of pharmaceutical companies, the IRS may propose increasing PBI's cost-sharing percentage by approximately 8–12 percentage points per year, effectively asserting that PBI should have borne a larger share of the qualified R&D costs. If the IRS proposes a 10-percentage-point increase, the incremental cost-sharing payments that would flow from PBI to PPC could generate proposed adjustments in the range of $185 million to $260 million across all four examination years, depending on the specific adjustments proposed for each year.

3. Assessment of Defensibility

PPC's RAB methodology is consistent with the regulatory framework established by Treasury Regulation § 1.482-7 and is supported by contemporaneous documentation prepared by Crestfield. Revenue-based RAB is a widely accepted methodology in the pharmaceutical industry, and PPC's use of this methodology is not inherently vulnerable to challenge. The progressive increase in PBI's cost-sharing percentage is consistent with the documented growth in non-Americas revenue and is not indicative of any manipulation or result-oriented adjustment.

That said, the defensibility of the RAB percentages ultimately depends on the quality and reasonableness of the revenue projections used. Revenue projections are inherently forward-looking and involve significant judgment, which makes them a natural point of IRS challenge. The IRS may also argue that the projections were selectively optimistic for non-Americas markets, or that they failed to account for foreseeable adverse developments in those markets.

To strengthen PPC's defense, C&H has engaged Whitmore Valuation Group LLC to conduct an independent validation of PPC's RAB methodology and the revenue projections underlying the cost-sharing percentages for each examination year. The Whitmore engagement is structured under a Kovel arrangement (Kovel letter executed June 20, 2022; C&H reference 1018-00009-KV) to preserve attorney-client privilege over Whitmore's analysis and communications. The Whitmore engagement is led by Dr. Helena Vasquez, Managing Director, with support from Dr. Rohan Chakrabarti, Senior Director. Whitmore is headquartered at 200 Ashbury Asset Advisors, Suite 700, Boston, MA 02109.

Defensibility Assessment: Moderate to Strong. The RAB-based methodology is well-established and consistent with the regulatory framework, and PPC's documentation is thorough. However, the projection-dependent nature of the RAB percentages introduces inherent vulnerability, and the IRS will have the benefit of hindsight in evaluating the reasonableness of PPC's projections. We recommend that Whitmore prepare a comprehensive analysis demonstrating that PPC's projections were reasonable at the time they were made and that alternative projections — including those using actual results — do not materially alter the cost-sharing percentages.

B. Legacy IP Royalty Rate

1. PPC's Position

PPC's position is that the 4.5% royalty rate on legacy compound non-Americas net sales represents arm's-length compensation for PBI's use of PPC's intangible property, consistent with the standards of Treasury Regulation § 1.482-4. The royalty rate was established at the inception of the license agreement based on a comparable uncontrolled transaction ("CUT") analysis performed by Crestfield. The CUT analysis identified third-party pharmaceutical licensing agreements involving comparable intangible property, comparable therapeutic categories, and comparable market territories, and determined that the 4.5% royalty rate fell within the arm's-length range established by those comparable transactions.

Crestfield's contemporaneous transfer pricing documentation for each examination year reconfirms the arm's-length nature of the 4.5% royalty rate. The documentation includes the CUT analysis, a description of the comparable transactions used, and the methodology for selecting and adjusting those comparables. The CUT method was selected as the "best method" under Treasury Regulation § 1.482-1(c), based on the availability of reliable comparable data and the method's consistency with the guidance in Treasury Regulation § 1.482-4(c) for pricing intangible property transactions.

2. Potential IRS Challenge

The IRS is likely to assert that the 4.5% royalty rate substantially understates the arm's-length royalty for pharmaceutical IP of this nature and value. In recent transfer pricing examinations of pharmaceutical companies, the IRS has consistently challenged royalty rates in the 4%–6% range as below arm's length, proposing rates in the range of 10%–15% for pharmaceutical IP with characteristics similar to PPC's legacy compounds.

The IRS may conduct its own CUT analysis, selecting a different set of comparable third-party licensing agreements that yield higher royalty rates. Common points of dispute in CUT analyses include the comparability of the therapeutic category, the stage of product development, the size and scope of the licensed territory, the profit potential of the licensed products, and the presence or absence of exclusivity provisions, co-promotion rights, and milestone payments. The IRS may also argue that PPC's selected comparables are not sufficiently comparable to PPC's legacy compounds — for example, because PPC's comparables involve less valuable IP, smaller markets, or different risk profiles — and may substitute its own comparables that yield higher royalty rates.

Based on our review of recent IRS examination outcomes and litigated cases involving pharmaceutical royalty rates, we would expect the IRS to propose a royalty rate in the range of 9%–12%. At a proposed rate of 11%, the incremental royalty adjustment across all four examination years would approximate $186 million to $190 million, calculated as follows:

The declining legacy net sales base somewhat mitigates the exposure, as the incremental adjustment decreases in absolute terms over the four-year period. However, the aggregate exposure remains substantial.

3. Assessment of Defensibility

The CUT analysis will be a central battleground in this examination. The defensibility of PPC's 4.5% royalty rate depends critically on the comparability and quality of the CUT agreements used in Crestfield's analysis, and on PPC's ability to demonstrate that its selected comparables are more reliable and probative than any alternative comparables the IRS may identify.

CUT analyses are inherently fact-intensive, and comparability disputes are among the most common and contentious issues in transfer pricing litigation. The IRS will likely challenge the degree of comparability between PPC's selected transactions and the controlled transaction, focusing on differences in product characteristics, profit potential, geographic scope, and contractual terms. PPC must be prepared to defend the comparability of its CUT agreements through detailed adjustments and a rigorous comparability analysis.

C&H has directed Whitmore to conduct an independent CUT analysis, identifying comparable pharmaceutical license agreements from publicly available databases (including Vireo Health IT, Sundial Health IT, and SEC filings) and establishing the interquartile range ("IQR") for the arm's-length royalty rate. The goal of this analysis is to confirm that PPC's 4.5% rate falls within the IQR of reliable comparables, which would provide PPC with penalty protection under Treasury Regulation § 1.482-4(d)(2) and strengthen PPC's factual position in any dispute.

Defensibility Assessment: Moderate. CUT analyses are inherently vulnerable to IRS challenge, and comparability disputes are common. The pharmaceutical licensing landscape is highly heterogeneous, and it is possible that the IRS will identify comparables that support a higher royalty rate. However, if Whitmore can identify a robust set of comparables supporting an IQR that includes 4.5%, PPC's position should be sustainable, particularly if the comparables are drawn from transactions involving similar therapeutic categories, product lifecycle stages, and geographic scopes.

C. Platform Contribution Transaction Valuation

1. PPC's Position

On July 1, 2012, PBI made a lump-sum PCT payment of $312 million to PPC as consideration for a buy-in to PPC's pre-existing pharmaceutical IP portfolio for the non-Americas territory. The PCT was valued at the time of the transaction using an income method / Discounted cash flow ("DCF") approach, consistent with the methodologies prescribed in Treasury Regulation § 1.482-7(g)(4) for valuing platform contributions to qualified cost-sharing arrangements.

The DCF valuation reflected the expected future cash flows from PBI's exploitation of the contributed IP in the non-Americas territory, discounted to present value using a weighted average cost of capital ("WACC") determined to be appropriate for pharmaceutical IP of this nature and risk profile. The valuation was performed by Crestfield and documented in the contemporaneous transfer pricing report for Tax Year 2012.

2. Potential IRS Challenge

Although Tax Year 2012 falls outside the four-year examination window, the IRS may use a PCT undervaluation theory to challenge the ongoing CSA economics for Tax Years 2017–2020. This approach has been employed by the IRS in several recent examinations and litigated cases, and is based on the theory that an understated PCT payment creates a systemic distortion in the CSA that persists throughout the life of the arrangement.

Specifically, the IRS may argue that the $312 million PCT payment was substantially below the arm's-length value of the contributed IP, and that a higher PCT payment — potentially $800 million or more — would have been required to compensate PPC adequately for the pre-existing IP. The shortfall in the initial payment, the IRS may argue, effectively subsidized PBI's participation in the CSA and allowed PBI to retain a disproportionate share of the residual returns from the contributed IP during the examination years.

The IRS's income-method valuation may differ from PPC's in several respects, including the discount rate applied, the revenue and profit projections used, the growth assumptions, and the terminal value methodology. In particular, the IRS may argue that PPC used an overly high discount rate (which reduces the present value of future cash flows and thus reduces the PCT value), or that PPC's revenue projections at the time of the PCT underestimated the commercial potential of the contributed IP — particularly Veritaxol, which became a blockbuster product generating over $3 billion in annual global revenue by 2020.

3. Assessment of Defensibility

The PCT valuation will require a thorough re-examination using the data available at the time of the 2012 transaction, as well as an analysis of how the PCT valuation interacts with the ongoing CSA cost-sharing adjustments for the 2017–2020 period.

The key variables in the DCF analysis are the discount rate (WACC) applied and the revenue projections used. C&H has directed Whitmore to prepare an independent DCF analysis of the PCT using a defensible WACC and revenue projections that were reasonable as of July 1, 2012. Whitmore's preliminary view, based on an initial review of the underlying data, is that a WACC in the range of 9%–10% is appropriate for pharmaceutical IP of this type and risk profile — reflecting the inherent uncertainty in pharmaceutical product development, regulatory approval timelines, and market adoption rates. At a WACC in this range, Whitmore anticipates that its DCF analysis would support a PCT value range that brackets PPC's $312 million payment, thereby confirming that the PCT was within the arm's-length range.

It is critical to note that the reasonableness of the PCT valuation must be assessed based on the information available at the time of the transaction (July 2012), not with the benefit of hindsight regarding the subsequent commercial success of Veritaxol and other contributed compounds. The IRS has historically attempted to incorporate hindsight data into its PCT valuations, but this approach has been challenged successfully by taxpayers in several Tax Court cases, and the regulations require that the valuation be based on "the most reliable measure of an arm's length charge" at the time of the transaction.

The link between the PCT valuation and the ongoing CSA adjustments introduces additional complexity. If the IRS argues that the PCT was understated, it may attempt to recharacterize the ongoing CSA cost-sharing payments as including a deferred component of the PCT, which would increase the effective cost-sharing payments flowing from PBI to PPC. This argument would need to be addressed in conjunction with the CSA cost-sharing ratio analysis discussed in Section IV.A above.

Defensibility Assessment: Moderate to Strong on the PCT valuation itself, provided that PPC can demonstrate that the WACC and revenue projections used in the 2012 valuation were reasonable at the time. The connection between the PCT and the ongoing CSA adjustments adds complexity, but PPC's overall CSA framework is defensible if the PCT is shown to be within the arm's-length range.

D. PBI Economic Substance and DEMPE Functions

1. PPC's Position

PPC's position is that PBI has substantial economic substance in Ireland and performs key DEMPE functions that justify its role as the IP-holding company and CSA participant for the non-Americas territory. The factual evidence supporting PBI's substance and functional contributions includes the following:

• Personnel: PBI employed 185 individuals as of December 31, 2020, a significant increase from the 52 employees at the time of PBI's incorporation in March 2012. PBI's employees include experienced pharmaceutical professionals in regulatory affairs, medical affairs, commercial strategy, supply chain management, and finance.

• Management: PBI is led by Managing Director Aidan Naughton, who is resident in Ireland and exercises day-to-day management authority over PBI's operations.

• Governance: PBI's board of directors held 42 meetings during the 2017–2020 period — approximately quarterly plus additional special sessions — all of which were held in Dublin. The board meeting minutes reflect substantive deliberation on key commercial, regulatory, and strategic matters.

• Office Facilities: PBI maintains approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, which houses PBI's operational teams and management.

• Regulatory Expenditures: PBI incurred cumulative regulatory expenditures of approximately €47.2 million during the 2017–2020 period on regulatory submissions and post-approval activities in non-Americas markets.

• Commercial Decision-Making: PBI makes independent pricing decisions across 68 country markets, selects and manages distribution partners, determines market entry sequencing, and develops commercial strategies tailored to local market conditions in the EMEA and Asia-Pacific regions.

• Local Banking: PBI maintains its primary banking relationship with Glenmore Bank Ireland plc and manages its treasury functions locally in Dublin.

With respect to the specific DEMPE functions, PPC's position is as follows:

• Development: Development functions are shared through the CSA, with PBI co-funding R&D proportionate to its RAB share. While the majority of laboratory-based R&D is conducted at PPC's U.S. facilities, PBI's contribution to the cost of development constitutes meaningful participation in the development function.

• Enhancement: PBI performs Enhancement functions, including local formulation adaptations to meet regional regulatory requirements, clinical data package modifications for non-Americas regulatory submissions, and post-approval studies and label extensions in PBI's territory.

• Maintenance: PBI performs Maintenance functions, including pharmacovigilance, quality oversight of contract manufacturing operations (through PMI and third-party manufacturers), and ongoing regulatory compliance in non-Americas markets.

• Protection: PBI is responsible for the registration and enforcement of PPC's IP rights in non-Americas jurisdictions, including patent filings, trademark registrations, and coordination of anti-counterfeiting efforts.

• Exploitation: PBI performs the full range of Exploitation functions in its territory, including commercialization, distribution partner management, pricing, reimbursement negotiations, medical education, and promotional activities across 68 country markets.

2. Potential IRS Challenge

The IRS may argue that PBI's claimed substance and functional contributions are insufficient to justify its role as IP owner and CSA participant, and that the critical Development and Enhancement functions — particularly core R&D, clinical trials management, and strategic IP portfolio decisions — remained in the United States under PPC's control throughout the examination period.

The IRS's argument may take one or more of the following forms:

(a) "Cash box" Characterization. The IRS may characterize PBI as a "cash box" or limited-function entity — an entity that holds IP rights on paper and receives substantial income, but lacks the personnel, expertise, and decision-making authority to justify its role as IP owner. Under this characterization, PBI would be treated as, at most, a contract distributor or limited-risk licensee entitled to a routine return, with the residual returns attributed to PPC in the United States.

(b) Control of Key Functions. The IRS may argue that PPC's U.S.-based R&D team exercised de facto control over all material intangible development activities, including the selection of R&D priorities, the design of clinical trials, the interpretation of clinical data, and the strategic decisions regarding IP portfolio management. If the IRS can establish that these functions were controlled from the U.S., it would undermine the premise that PBI's cost-sharing payments entitle it to a share of the residual returns from the resulting IP.

(c) Personnel-Based Analysis. The IRS may conduct a personnel-based analysis comparing the number, seniority, and functional responsibilities of PPC's U.S.-based R&D and commercial personnel against PBI's 185 Dublin-based employees. To the extent that PPC's U.S. operations employ a substantially larger number of R&D professionals and senior decision-makers, the IRS may argue that the balance of functions and decision-making authority is weighted toward the United States.

If the IRS succeeds in establishing that PBI lacks sufficient substance or fails to perform adequate DEMPE functions, this finding would support both the CSA and royalty adjustments by undermining the premise that PBI is entitled to the residual returns it currently earns from non-Americas exploitation.

3. Assessment of Defensibility

This is an area where PPC has strong factual defenses, but the evidence must be carefully marshaled and presented. The growth in PBI's headcount from 52 employees at incorporation to 185 employees by 2020 demonstrates a substantial and sustained investment in building operational capabilities in Ireland. The 42 board meetings held in Dublin during the four-year examination period, the €47.2 million in cumulative regulatory expenditures, and the demonstrated independence in commercial decisions across 68 country markets are all powerful evidence of genuine economic substance and functional contributions.

However, the IRS will likely attempt to look beyond the surface-level headcount and governance metrics to probe the quality and independence of PBI's decision-making. The IRS may seek to establish that PBI's board meetings were largely pro forma, that key decisions were effectively pre-determined by PPC's U.S. management, or that PBI's commercial strategy was dictated by PPC's global commercial leadership rather than independently developed in Dublin. These allegations can be rebutted with a thorough factual record, but the rebuttal must be grounded in specific, documented evidence of independent PBI decision-making.

C&H will prepare a comprehensive functional analysis documenting PBI's activities, personnel, decision-making processes, and risk management functions during the 2017–2020 period. This analysis will include:

• Interviews of 12 key PBI employees in Dublin, conducted by C&H attorneys (Simmons and Nazari) at PBI's offices, to document each employee's role, responsibilities, decision-making authority, and functional contributions.

• A detailed analysis of all 42 PBI board meetings (2017–2020), including a review of board minutes, board presentations, and board resolutions, to document the scope and substance of the board's deliberations and the independence of its decision-making.

• A DEMPE functions matrix allocating specific DEMPE functions between PPC and PBI for each product line (Veritaxol, Imvara, Cerulon, and legacy compounds), with supporting evidence drawn from organizational charts, job descriptions, internal communications, and decision memoranda.

Defensibility Assessment: Strong, provided we can thoroughly document PBI's functions and present the evidence persuasively. The factual record supports PBI's substance, and the IRS's "cash box" characterization should be refutable given the scope of PBI's operations. The key risk is that PBI's decision-making may be perceived as derivative of or subordinate to PPC's global strategy, and this perception must be addressed head-on through careful documentation of PBI's independent contributions.

V. Preliminary Exposure Quantification

A. Potential Adjustment Ranges

Based on C&H's experience with similar IRS transfer pricing examinations of pharmaceutical companies and our preliminary analysis of PPC's positions, we estimate the following potential adjustment ranges for the four examination years:

CSA Cost-Sharing Adjustments. If the IRS proposes increasing PBI's cost-sharing percentage by approximately 10 percentage points per year — from PPC's reported percentages of 38.2%–42.7% to IRS-proposed percentages of approximately 48%–53% — the incremental cost-sharing payments that would flow from PBI to PPC could total approximately $230 million to $240 million across all four examination years. The specific calculation for each year is as follows:

Royalty Rate Adjustments. If the IRS proposes a royalty rate of 10%–12% (compared to PPC's 4.5%), the incremental royalties that would flow from PBI to PPC could total approximately $160 million to $210 million across all four examination years, as detailed in Section IV.B.2 above.

Correlative Offsets. Any adjustments to both the CSA cost-sharing payments and the legacy IP royalty rate would need to account for overlap and correlative effects. To the extent that both adjustments are premised on the theory that PPC contributed more value than was reflected in the existing arrangements, there is a risk of double-counting the same income. Correlative adjustments or offsets could reduce the net adjustment by approximately $30 million to $50 million. The specific correlative analysis will depend on the IRS's articulation of its adjustments and the interaction between the CSA and royalty theories.

Preliminary Net Exposure Range. Combining the CSA and royalty adjustments and accounting for correlative offsets, we estimate a preliminary net exposure range of approximately $340 million to $400 million in proposed Section 482 adjustments across all four examination years. This represents the aggregate increase in PPC's U.S.-source taxable income that the IRS may propose.

B. Tax and Penalty Implications

Federal Income Tax. At a 21% federal corporate income tax rate — applicable to Tax Years 2018, 2019, and 2020 — a proposed adjustment of $380 million (the midpoint of our estimated range) would generate approximately $80 million in proposed additional federal income tax. For Tax Year 2017, the applicable rate is a blended rate reflecting the 35% rate in effect prior to the Tax Cuts and Jobs Act ("TCJA") and the 21% rate effective for taxable years beginning after January 1, 2018. The specific computation for TY 2017 will depend on PPC's fiscal year-end and the mechanics of the blended rate calculation, but the effective rate for TY 2017 is likely in the range of 26%–28%.

Substantial Valuation Misstatement Penalty. The IRS may assert the IRC § 6662(e) substantial valuation misstatement penalty at a rate of 20% on the net Section 482 allocation. For a proposed adjustment of $380 million generating approximately $80 million in additional tax, the 20% penalty could add approximately $16 million. The IRS may also reserve the right to assert the IRC § 6662(h) gross valuation misstatement penalty at a rate of 40%, although based on our assessment of PPC's documentation, we do not believe the IRS would have a strong basis for asserting the 40% penalty. PPC's contemporaneous transfer pricing documentation, prepared by Crestfield in accordance with the penalty-protection standards of IRC § 6662(e)(3)(B), should provide a reasonable-cause defense against the penalty, though the strength of this defense will depend on the quality and completeness of the documentation and the extent to which it supports PPC's specific transfer pricing positions.

Interest. Interest on any underpayment would accrue at the applicable federal underpayment rate (currently the federal short-term rate plus 3 percentage points, compounded daily) from the original due dates of the returns for each examination year through the date of payment. Given the multi-year span of the examination, the interest accumulation could be significant, though a precise calculation is not possible until the timing and amount of any settlement or assessed deficiency is known.

Total Preliminary Worst-Case Exposure. Based on the foregoing analysis, PPC's total preliminary worst-case exposure is estimated at approximately:

• Federal income tax: approximately $80 million

• Section 6662(e) penalty (20%): approximately $16 million

• Interest: to be determined (dependent on timing of resolution)

• Total: approximately $96 million+ before interest

We emphasize that this is a worst-case estimate based on the upper end of the potential adjustment range and the assumption that the IRS prevails on all issues. In practice, the actual exposure is likely to be substantially lower if PPC's defense is effective, and particularly if the case is resolved through IRS Appeals on a hazards-of-litigation basis.

C. Interaction with GILTI and BEAT

For Tax Years 2018, 2019, and 2020, any Section 482 adjustment that increases PPC's U.S.-source income and correspondingly reduces PBI's income could interact with PPC's Global Intangible Low-Taxed Income ("GILTI") position under IRC § 951A and its Base Erosion and Anti-Abuse Tax ("BEAT") position under IRC § 59A.

Under GILTI, PPC is required to include in its U.S. taxable income its pro rata share of PBI's "tested income" (net of the deemed tangible income return). A reduction in PBI's income as a result of a Section 482 adjustment would reduce PPC's GILTI inclusion, which would partially offset the increase in PPC's U.S.-source income from the Section 482 adjustment itself. The net tax effect of the Section 482 adjustment must therefore be computed on an after-GILTI basis.

Similarly, a Section 482 adjustment that reduces intercompany payments from PPC to PBI (or increases payments fr

PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT This memorandum is a privileged and confidential communication prepared by Calderwood & Harkness LLP at the direction of legal counsel for Penterra Pharmaceuticals Corp. It is protected from disclosure by the attorney-client privilege, the work-product doctrine, and any other applicable privilege or protection. This memorandum is intended solely for the use of the addressees and should not be disclosed, copied, or distributed to any third party without the prior written consent of Calderwood & Harkness LLP.
MEMORANDUM
TO: Marcus Whitfield, Vice President, Global Tax, Penterra Pharmaceuticals Corp. Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp.
FROM: Leonard Cross, Partner, Calderwood & Harkness LLP Garrett Simmons, Associate, Calderwood & Harkness LLP
DATE: June 15, 2022
RE: Preliminary Assessment — IRS Large Business & International Division Examination of Penterra Pharmaceuticals Corp. Transfer Pricing (Tax Years 2017–2020)
C&H Matter No.: 1018-00009
Right-click to update Table of Contents
I. Executive Summary
Calderwood & Harkness LLP ("C&H") was retained on June 2, 2022, to represent Penterra Pharmaceuticals Corp. ("PPC" or the "Company") in connection with an examination opened by the Internal Revenue Service Large Business & International Division ("LB&I") on May 16, 2022. The examination was initiated by Letter 2205-A and has been assigned Exam Team ID LB&I-NE-TP-2022-00641. The examination covers PPC's consolidated federal income tax returns (Forms 1120) for Tax Years 2017, 2018, 2019, and 2020.
Based on our review of the initial contact letter, the composition of the IRS examination team, and our preliminary analysis of PPC's intercompany arrangements, the examination is focused on PPC's transfer pricing arrangements with its Irish subsidiary, Penterra Biopharma International DAC ("PBI"). Specifically, we believe the IRS will concentrate its inquiry on three core areas: (a) the cost-sharing arrangement ("CSA") between PPC and PBI, including the reasonably anticipated benefits ("RAB") methodology used to allocate qualified R&D costs; (b) the legacy IP royalty arrangement under which PBI licenses pre-2012 compounds from PPC for non-Americas commercialization at a royalty rate of 4.5% of net sales; and (c) the 2012 platform contribution transaction ("PCT") under which PBI made a lump-sum payment of $312 million to PPC as consideration for a buy-in to pre-existing pharmaceutical intellectual property.
On June 8, 2022, IRS Form 2848 (Power of Attorney and Declaration of Representative) was filed with the Internal Revenue Service authorizing Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari, all of Calderwood & Harkness LLP, to represent PPC before the IRS in connection with this examination for Tax Years 2017 through 2020.
This memorandum provides our initial assessment of: (a) the scope and posture of the examination, including the composition and likely approach of the IRS examination team; (b) PPC's current transfer pricing positions and their defensibility under applicable Treasury Regulations, case law, and OECD Transfer Pricing Guidelines; (c) potential exposure areas and a preliminary quantification of the financial risk to PPC, including tax, penalty, and interest implications; and (d) recommended next steps for organizing and executing PPC's defense.
We note that PPC was not enrolled in the IRS Compliance Assurance Process ("CAP") for any of the tax years at issue, and accordingly there has been no prior interaction with the IRS regarding the transfer pricing positions now under examination. This is the first comprehensive IRS examination of PPC's international tax structure since the CSA was entered into in 2012.
Overall Assessment: Based on our preliminary review, PPC's transfer pricing positions are well-documented and defensible, supported by contemporaneous transfer pricing reports prepared by Crestfield & Associates LLP ("Crestfield") and grounded in methodologies prescribed by the applicable Treasury Regulations. However, certain areas — most notably the legacy IP royalty rate and the projection-dependent RAB cost-sharing percentages — present moderate risk and will require focused preparation and, potentially, supplemental economic analysis. We have engaged Whitmore Valuation Group LLC ("Whitmore") under a Kovel arrangement to provide independent economic analysis in support of the defense. The sections that follow set forth our detailed findings and recommendations.
II. Background — PPC's Corporate Structure and IP Arrangements
A. Corporate Structure Overview
Penterra Pharmaceuticals Corp. is a corporation organized under the laws of the State of Delaware and publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. PPC's principal executive offices are located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company whose therapeutic focus areas include oncology, immunology, and rare-disease therapeutics.
For the fiscal year ended December 31, 2020, PPC reported consolidated global revenue of approximately $6.82 billion, consolidated pre-tax income of approximately $1.47 billion, and employed approximately 14,500 individuals globally across its U.S. headquarters, research and development facilities, and international subsidiaries and affiliates.
PPC's senior management team during the examination period included Catherine Falk as Chief Executive Officer, Rajesh Iyer as Chief Financial Officer, Deborah Staines as General Counsel, and Marcus Whitfield as Vice President, Global Tax.
PPC's international corporate structure relevant to this examination is organized as follows:
• Penterra Pharmaceuticals Corp. ("PPC") — Delaware corporation; ultimate U.S. parent entity; headquartered at 2200 Independence Boulevard, Princeton Junction, NJ 08550.
• Penterra Holdings Luxembourg S.à r.l. ("PHL") — A société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg; registered at 14, rue Aldringen, L-1118 Luxembourg; Luxembourg Registre de Commerce et des Sociétés ("RCS") No. B 168452. PHL is wholly owned by PPC and is treated as a disregarded entity for U.S. federal income tax purposes. PHL serves as an intermediate holding company for PPC's European operations.
• Penterra Biopharma International DAC ("PBI") — A Designated Activity Company organized under Irish law; registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland; Irish Companies Registration Office ("CRO") No. 489216; Irish Tax Reference No. 3218764T. PBI is wholly owned by PHL. PBI serves as the intellectual property holding company and commercial principal for PPC's non-Americas territories. Aidan Naughton serves as Managing Director. As of December 31, 2020, PBI employed 185 individuals, a significant increase from the 52 employees at the time of PBI's incorporation in March 2012.
• Penterra Manufacturing Ireland Ltd. ("PMI") — An Irish limited company; registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland; Irish CRO No. 512347. PMI is wholly owned by PBI and operates as a contract manufacturer of PPC's oncology and immunology biologic products for non-Americas markets. PMI operates under a cost-plus transfer pricing arrangement with PBI, receiving cost plus an 8% markup for manufacturing services. PMI employs approximately 620 individuals at its Ringaskiddy facility.
This corporate structure has been in place since 2012, when PBI was incorporated and the cost-sharing arrangement was entered into. The structure was designed to centralize PPC's non-Americas intellectual property ownership and commercialization functions in Ireland, leveraging Ireland's favorable corporate tax regime (12.5% on trading income) and the availability of Ireland's Knowledge Development box ("KDB") regime (effective rate of 6.25% on qualifying IP income), which PBI has claimed from fiscal year 2016 forward.
B. The Cost-Sharing Arrangement
PBI was incorporated on March 15, 2012. Effective July 1, 2012, PPC and PBI entered into a qualified Cost-Sharing Arrangement (the "CSA") pursuant to which PBI acquired the right to develop and exploit PPC's pharmaceutical IP portfolio outside the Americas region. For purposes of the CSA, the "Americas" territory is defined to include North America (the United States, Canada, and Mexico), Central America, South America, and the Caribbean. All other territories — including Europe, the Middle East, Africa, and Asia-Pacific — constitute PBI's territory under the CSA.
The CSA was structured in accordance with the requirements of Treasury Regulation § 1.482-7, governing qualified cost-sharing arrangements. As consideration for PBI's buy-in to the pre-existing intellectual property contributed by PPC to the CSA, PBI made a lump-sum platform contribution transaction payment of $312 million to PPC on July 1, 2012. The pre-existing IP contributed by PPC consisted primarily of clinical-stage and approved oncology compounds, including the precursor formulations and clinical data packages for what would become PPC's blockbuster oncology product, Veritaxol.
Under the ongoing terms of the CSA, PBI makes cost-sharing payments to PPC on an annual basis, proportional to PBI's reasonably anticipated benefits from the intangible development activities funded by the CSA. The RAB methodology is based on projected revenue splits between the Americas territory (PPC's area) and the non-Americas territory (PBI's area), applied to the total qualified R&D cost pool.
PBI's share of annual qualified R&D costs during the examination years was as follows:
The progressive increase in PBI's cost-sharing percentage — from 38.2% in Tax Year 2017 to 42.7% in Tax Year 2020 — reflects the organic growth of PPC's non-Americas business, driven primarily by the successful commercialization of Veritaxol and Imvara in European and Asia-Pacific markets during this period. These percentages were recalculated each year based on updated revenue projections for each territory, as prescribed by the CSA agreement and consistent with the methodology documented in Crestfield's contemporaneous transfer pricing reports.
C. The Legacy IP Royalty Arrangement
Separately from and in addition to the CSA, PBI licenses certain legacy pharmaceutical compounds from PPC under a license agreement entered into contemporaneously with the CSA. The legacy compounds consist of pre-2012 vintage products that were not included within the scope of the CSA's intangible development activities but for which PBI was granted exclusive commercialization rights in the non-Americas territory.
Under this license agreement, PBI pays PPC a royalty of 4.5% of net sales for the non-Americas territory. The royalty rate was established based on a comparable uncontrolled transaction ("CUT") analysis performed by Crestfield at the time the license was entered into. The arrangement was structured in accordance with Treasury Regulation § 1.482-4, which sets forth methods to determine the arm's-length consideration for the transfer of intangible property.
Legacy compound non-Americas net sales and corresponding royalty payments during the examination years were as follows:
The declining trajectory in legacy compound net sales reflects the natural lifecycle of the pre-2012 product portfolio, as these compounds have progressively lost market share to newer products developed under the CSA. The total royalty income received by PPC from the legacy license over the four-year examination period was approximately $130.17 million.
D. Key Products
PPC's product portfolio includes three major therapeutic products that account for the substantial majority of its global revenue:
Veritaxol (Oncology). Veritaxol is PPC's blockbuster oncology product, a monoclonal antibody therapy indicated for the treatment of non-small cell lung cancer and certain other solid tumors. Veritaxol was approved by the U.S. Food and Drug Administration in 2014 and has subsequently received regulatory approval in over 60 countries worldwide. For fiscal year 2020, Veritaxol generated global net sales of approximately $3.12 billion, of which approximately $1.34 billion (approximately 43% of global sales) was attributable to non-Americas markets within PBI's territory.
Imvara (Immunology). Imvara is PPC's leading immunology product, indicated for the treatment of moderate-to-severe rheumatoid arthritis and psoriatic arthritis. Imvara received FDA approval in 2016 and has been commercially launched in approximately 45 countries. For fiscal year 2020, Imvara generated global net sales of approximately $1.87 billion, of which approximately $0.79 billion (approximately 42% of global sales) was attributable to non-Americas markets.
Cerulon (Rare Disease). Cerulon is an enzyme replacement therapy for the treatment of a rare lysosomal storage disorder. Cerulon received FDA approval in 2013 and has obtained orphan drug designation in several jurisdictions. For fiscal year 2020, Cerulon generated global net sales of approximately $0.62 billion, of which approximately $0.28 billion (approximately 45% of global sales) was attributable to non-Americas markets.
The geographic distribution of revenues for these products is a critical input to the RAB methodology used in the CSA, and any IRS challenge to the cost-sharing percentages will necessarily involve a detailed examination of the revenue allocation between PPC's Americas territory and PBI's non-Americas territory for each product line.
E. PBI's Functions, Assets, and Risks
A thorough understanding of PBI's operations in Ireland is essential to PPC's defense, particularly with respect to any IRS challenge to PBI's economic substance and DEMPE functions. Based on our preliminary review of PPC's transfer pricing documentation and our initial discussions with PPC management, PBI's operational profile is as follows:
Functions. PBI functions as the intellectual property holding company and commercial principal for all of PPC's non-Americas operations. PBI manages contract manufacturing arrangements with PMI (and, for certain products, with third-party contract manufacturers in Germany and Singapore), oversees distribution arrangements across 68 country markets in the EMEA and Asia-Pacific regions, and bears primary responsibility for regulatory, medical-affairs, commercial-strategy, and supply-chain functions in the non-Americas territory. PBI maintains a team of experienced pharmaceutical professionals in Dublin who perform the following key functions:
• Regulatory affairs: PBI's regulatory team manages all regulatory submissions, market authorization applications, and post-approval commitments for non-Americas markets, including submissions to the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency, and over 50 national regulatory authorities. During the 2017–2020 period, PBI incurred cumulative regulatory expenditures of approximately €47.2 million on these submissions and related activities.
• Medical affairs: PBI employs medical science liaisons and medical directors responsible for post-marketing surveillance, pharmacovigilance reporting, medical information, and medical education programs in the non-Americas territory.
• Commercial strategy: PBI makes key commercial decisions including product pricing, market entry sequencing, distribution partner selection and management, and promotional strategy across its 68 country markets. These decisions are made by PBI's commercial leadership team in Dublin, subject to oversight by PBI's board of directors.
• Supply chain management: PBI manages the supply chain for non-Americas markets, coordinating with PMI and third-party contract manufacturers to ensure product availability, inventory management, and quality control.
Assets. PBI holds the rights to PPC's pharmaceutical IP for the non-Americas territory under the CSA, as well as the licensed rights to legacy compounds under the royalty arrangement. PBI also holds intangible assets in the form of regulatory dossiers, market authorizations, and distribution agreements in non-Americas markets. PBI maintains approximately 18,000 square feet of office space at Sandyford Business Park in Dublin.
Risks. PBI bears significant market risk for non-Americas territories, including pricing risk, competitive risk, regulatory risk, and foreign currency risk. PBI is responsible for commercial outcomes in its territory and absorbs losses in the event of adverse market developments, regulatory setbacks, or competitive pressures. PBI also bears the risk associated with its share of R&D costs under the CSA, as there is no guarantee that the R&D activities funded through the CSA will result in commercially viable products.
Governance. PBI's board of directors met 42 times during the 2017–2020 period — approximately quarterly plus additional special sessions convened to address significant commercial, regulatory, and strategic matters. All board meetings were held in Dublin. The board's meeting minutes reflect substantive deliberation on key commercial decisions, including pricing strategies, market entry decisions, and responses to competitive developments in non-Americas markets.
Financial Profile. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI's Irish effective tax rate on trading income was 12.5%, and PBI claimed benefits under Ireland's Knowledge Development box at an effective rate of 6.25% on qualifying IP income from fiscal year 2016 forward. PBI maintains its primary banking relationship with Glenmore Bank Ireland plc and manages its treasury functions locally in Dublin.
Irish Tax Advisory. PBI's Irish tax compliance and advisory services are provided by Thornbury & Keogh, Chartered Tax Advisors, Dublin (Lead Partner: Ciarán Thornbury; 22 Fitzwilliam Square, Dublin 2, D02 YH68, Ireland). Thornbury & Keogh has advised PBI since its incorporation in 2012 and has been instrumental in securing PBI's Knowledge Development box benefits and managing PBI's relationship with the Irish Revenue Commissioners.
F. Contemporaneous Transfer Pricing Documentation
PPC's contemporaneous transfer pricing documentation for all four tax years under examination (2017–2020) was prepared by Crestfield & Associates LLP ("Crestfield"). The engagement was led by Martin Ogilvy, CPA (Engagement Partner) and Susan Lam, CPA (Transfer Pricing Partner). Crestfield is located at 1200 Avenue of the Americas, New York, NY 10036.
The transfer pricing documentation was prepared in accordance with the penalty-protection standards of IRC § 6662(e) and follows the methodologies prescribed in Treasury Regulations §§ 1.482-4 and 1.482-7. The documentation includes, among other things, (a) a description of PPC's organizational structure and business operations; (b) a functional analysis of PPC and PBI; (c) a description of the CSA, including the RAB methodology and the annual cost-sharing calculations; (d) a description of the legacy IP royalty arrangement, including the CUT analysis supporting the 4.5% royalty rate; (e) the selection and application of the best method under the regulations; and (f) the economic analyses supporting PPC's transfer pricing positions.
C&H is coordinating with Crestfield for access to all return data, workpapers, and underlying analyses related to the four examination years. We have made an initial request to Susan Lam for a complete set of transfer pricing documentation, and we anticipate receiving the first production by early July 2022.
III. Scope and Posture of the IRS Examination
A. Examination Opening and Team
The IRS opened the examination by issuing Letter 2205-A, dated May 16, 2022, notifying PPC that its consolidated federal income tax returns for Tax Years 2017, 2018, 2019, and 2020 had been selected for examination. The examination has been assigned to the LB&I Northeast Transfer Pricing Practice, with Team ID LB&I-NE-TP-2022-00641.
The IRS examination team is composed of the following individuals, as identified in the initial contact letter and subsequent communications:
• Supervisory Revenue Agent / Team Manager: Gerald Meskill. Mr. Meskill will serve as the team manager for the examination, overseeing all aspects of the audit and serving as the primary decision-maker on the IRS side regarding the scope and direction of the examination.
• Lead Revenue Agent: Patricia Dunleavy. Ms. Dunleavy will serve as the day-to-day point of contact for the examination, issuing Information Document Requests, conducting interviews, and coordinating the IRS's factual investigation.
• IRS Economist: Dr. Alan Washburne, IRS Transfer Pricing Practice. Dr. Washburne is an economist within the IRS's Transfer Pricing Practice and will be responsible for conducting an independent economic analysis of PPC's transfer pricing positions, including benchmarking, valuation, and assessment of PPC's methodologies.
• IRS Office of Chief Counsel Attorney-Advisor: Franklin Rosario. Mr. Rosario will provide legal advice to the examination team on substantive tax law issues, including the application of IRC § 482, the Treasury Regulations governing cost-sharing arrangements, and relevant case law.
• IRS Office of Chief Counsel Senior Counsel: Donna Hirabayashi. Ms. Hirabayashi's involvement as senior counsel suggests that the Office of Chief Counsel is providing heightened oversight to this examination, which is consistent with an examination that the IRS views as having potential for significant proposed adjustments and possible litigation.
The composition of the IRS examination team is itself highly informative. The assignment of both an IRS economist (Dr. Washburne) and two Chief Counsel attorneys (Rosario and Hirabayashi) at the outset of the examination — rather than at a later stage after proposed adjustments have been developed — is a strong signal that the IRS views this as a significant examination that is likely to result in substantial proposed adjustments. In our experience with similar LB&I transfer pricing examinations of pharmaceutical companies, the early involvement of Chief Counsel is typically associated with examinations where the IRS intends to pursue formal adjustments and is prepared for potential litigation if the case cannot be resolved at exam level or through IRS Appeals.
B. Anticipated IRS Focus Areas
Based on the initial contact letter, the composition of the IRS examination team, and C&H's extensive experience with similar LB&I transfer pricing examinations of pharmaceutical and life sciences companies, we anticipate that the IRS will focus its inquiry on four primary areas:
1. PCT Valuation. The IRS is likely to scrutinize whether the $312 million PCT payment made by PBI to PPC on July 1, 2012, adequately compensated PPC for the pre-existing intellectual property transferred to PBI at the inception of the CSA. Although Tax Year 2012 is beyond the four-year examination window, the IRS may use any perceived PCT undervaluation as a basis for challenging the ongoing CSA economics during the 2017–2020 period. Specifically, the IRS may argue that an understated PCT payment distorts the CSA by allowing PBI to retain a disproportionate share of residual returns from the exploitation of the contributed IP. In recent LB&I examinations, the IRS has employed this approach to link PCT valuation disputes to adjustments in subsequent tax years, even when the PCT year itself is closed.
2. CSA Cost-Sharing Ratios. The IRS is likely to challenge whether PBI's cost-sharing percentages (38.2% in 2017 rising to 42.7% in 2020) accurately reflect PBI's reasonably anticipated benefits from the intangible development activities funded by the CSA. The IRS may argue that PPC's RAB projections overstate PBI's anticipated share of benefits and correspondingly understate PPC's share, resulting in an allocation of R&D costs that is not commensurate with income. The IRS may propose alternative allocation keys — such as operating profits rather than revenue — or may challenge the revenue projections themselves as insufficiently supportive of PBI's increasing cost-sharing percentages.
3. Legacy IP Royalty Rate. The IRS is likely to challenge whether the 4.5% royalty rate on legacy compound non-Americas net sales represents arm's-length compensation for the use of PPC's intangible property. In recent transfer pricing examinations of pharmaceutical companies, the IRS has consistently asserted that royalty rates in the range of 4%–5% substantially understate the arm's-length rate for pharmaceutical IP of this nature. The IRS may conduct its own CUT analysis using third-party pharmaceutical licensing agreements to support a significantly higher royalty rate.
4. PBI Economic Substance / DEMPE Functions. The IRS may challenge whether PBI has sufficient economic substance and performs adequate Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions to justify its role as the IP-holding company and CSA participant for the non-Americas territory. If the IRS can establish that critical development and enhancement functions — particularly core R&D, clinical trials management, and strategic IP portfolio decisions — remained in the United States under PPC's control, this would undermine the premise that PBI is entitled to the residual returns it currently earns from non-Americas exploitation. This argument, if successful, would provide support for both the CSA and royalty adjustments by recharacterizing PBI as a limited-function entity.
These four areas are interconnected, and the IRS is likely to pursue them as a coordinated theory: that PBI was undercharged for the initial IP buy-in (PCT), pays too little in ongoing cost-sharing (CSA), pays too little for legacy IP (royalties), and in any event lacks the substance to justify its current returns (DEMPE). PPC's defense must address each of these areas both individually and as part of a coherent overall narrative.
C. Expected Examination Process
Based on C&H's experience with LB&I transfer pricing examinations of comparable scope and complexity, we anticipate the following examination process:
IDR Phase (June 2022 through mid-to-late 2023). The IRS will issue a series of Information Document Requests seeking production of documents and data related to PPC's transfer pricing positions. We anticipate a minimum of 30–50 IDRs covering a wide range of topics, including the CSA agreement and amendments, the legacy license agreement, Crestfield's transfer pricing documentation and workpapers, R&D cost pool composition, revenue projections, PBI board minutes, organizational charts, personnel lists, intercompany agreements, and financial statements for PPC, PBI, and PMI. This phase is likely to span 12–18 months, during which the IRS will also conduct interviews of PPC and PBI personnel.
IRS Economic Analysis (Parallel Track). During the IDR phase, Dr. Washburne will conduct an independent economic analysis of PPC's transfer pricing arrangements. This analysis will likely include benchmarking studies identifying comparable companies and transactions, independent CUT analyses for the royalty rate, and a re-valuation of the PCT using the IRS's own assumptions regarding discount rates, revenue projections, and growth rates. The IRS economist's analysis will form the foundation for any proposed adjustments.
NOPA and 30-Day Letter (Anticipated late 2023). Following the IDR phase and the completion of the IRS's economic analysis, we expect the IRS to issue a Notice of Proposed Adjustment ("NOPA") setting forth the IRS's proposed transfer pricing adjustments, the legal and factual basis for each adjustment, and the proposed additional tax, penalties, and interest. The NOPA will be accompanied by a 30-Day Letter providing PPC the opportunity to file a formal Protest and request consideration by the IRS Independent Office of Appeals.
Appeals Phase (Anticipated 2024). If PPC disagrees with the proposed adjustments, we would recommend filing a formal Protest and seeking resolution through IRS Appeals. The Appeals process offers a significant opportunity for resolution, as Appeals Officers are authorized to consider the "hazards of litigation" in determining whether and on what terms to settle a case. In our experience, a substantial majority of transfer pricing cases in the pharmaceutical sector are resolved at Appeals without the need for litigation.
The early involvement of Chief Counsel (Rosario and Hirabayashi) suggests that the IRS may also be preparing for potential litigation in the U.S. Tax Court or the Court of Federal Claims in the event that the case cannot be resolved at exam level or through Appeals. While we believe litigation is unlikely given the defensibility of PPC's positions, PPC should be prepared for this contingency.
IV. Assessment of PPC's Transfer Pricing Positions
A. Cost-Sharing Arrangement — Cost-Sharing Ratios
1. PPC's Position
PPC's position is that PBI's cost-sharing percentages are based on a reasonable and consistently applied methodology for measuring PBI's reasonably anticipated benefits from the intangible development activities funded by the CSA. The RAB methodology employed by PPC uses projected revenue splits between the Americas territory (PPC's area) and the non-Americas territory (PBI's area) as the allocation key, consistent with the guidance set forth in Treasury Regulation § 1.482-7(e)(1), which provides that reasonably anticipated benefits are to be "measured on a basis that is consistent with the measurement of anticipated benefits used to determine the participants' cost sharing payments."
The RAB methodology has been consistently applied since the inception of the CSA in July 2012. Each year, PPC updates the revenue projections for each territory based on then-current market data, product lifecycle analysis, and commercial forecasts, and recalculates PBI's cost-sharing percentage accordingly. The progressive increase in PBI's cost-sharing percentage — from 38.2% in 2017 to 42.7% in 2020 — reflects the organic growth in PPC's non-Americas markets, particularly the strong uptake of Veritaxol in European and Asia-Pacific markets and the successful commercial launch of Imvara in those markets during this period.
The RAB methodology and the annual cost-sharing calculations are fully documented in Crestfield's contemporaneous transfer pricing reports for each tax year. These reports include detailed descriptions of the revenue projection methodology, the data sources used, the allocation calculations, and the resulting cost-sharing payments. The documentation was prepared in accordance with the penalty-protection standards of IRC § 6662(e) and satisfies the contemporaneous documentation requirements of Treasury Regulation § 1.482-7(k).
2. Potential IRS Challenge
We anticipate that the IRS will challenge PPC's RAB methodology and the resulting cost-sharing percentages on one or more of the following grounds:
(a) Revenue Projections. The IRS may argue that PPC's revenue projections for the non-Americas territory were overstated, resulting in an inflated RAB percentage for PBI and correspondingly understated cost-sharing payments. The IRS may point to differences between PPC's projections and actual results, or may substitute its own revenue projections based on different assumptions regarding market growth, pricing trends, or competitive dynamics.
(b) Allocation Key. The IRS may argue that revenue is not the most appropriate basis for measuring reasonably anticipated benefits, and may propose an alternative allocation key — such as operating profits or units sold — that would result in a different (likely lower) RAB percentage for PBI and a correspondingly higher cost-sharing burden.
(c) Intangible Development Activities. The IRS may assert that certain intangible development activities ("IDAs") funded through the CSA were disproportionately performed by PPC personnel in the United States, and that PBI's cost-sharing percentage should be adjusted to account for the fact that the U.S. R&D team performed a greater share of the value-creating work. This argument may be linked to the DEMPE challenge discussed in Section IV.D below.
Based on precedent in similar LB&I examinations of pharmaceutical companies, the IRS may propose increasing PBI's cost-sharing percentage by approximately 8–12 percentage points per year, effectively asserting that PBI should have borne a larger share of the qualified R&D costs. If the IRS proposes a 10-percentage-point increase, the incremental cost-sharing payments that would flow from PBI to PPC could generate proposed adjustments in the range of $185 million to $260 million across all four examination years, depending on the specific adjustments proposed for each year.
3. Assessment of Defensibility
PPC's RAB methodology is consistent with the regulatory framework established by Treasury Regulation § 1.482-7 and is supported by contemporaneous documentation prepared by Crestfield. Revenue-based RAB is a widely accepted methodology in the pharmaceutical industry, and PPC's use of this methodology is not inherently vulnerable to challenge. The progressive increase in PBI's cost-sharing percentage is consistent with the documented growth in non-Americas revenue and is not indicative of any manipulation or result-oriented adjustment.
That said, the defensibility of the RAB percentages ultimately depends on the quality and reasonableness of the revenue projections used. Revenue projections are inherently forward-looking and involve significant judgment, which makes them a natural point of IRS challenge. The IRS may also argue that the projections were selectively optimistic for non-Americas markets, or that they failed to account for foreseeable adverse developments in those markets.
To strengthen PPC's defense, C&H has engaged Whitmore Valuation Group LLC to conduct an independent validation of PPC's RAB methodology and the revenue projections underlying the cost-sharing percentages for each examination year. The Whitmore engagement is structured under a Kovel arrangement (Kovel letter executed June 20, 2022; C&H reference 1018-00009-KV) to preserve attorney-client privilege over Whitmore's analysis and communications. The Whitmore engagement is led by Dr. Helena Vasquez, Managing Director, with support from Dr. Rohan Chakrabarti, Senior Director. Whitmore is headquartered at 200 Ashbury Asset Advisors, Suite 700, Boston, MA 02109.
Defensibility Assessment: Moderate to Strong. The RAB-based methodology is well-established and consistent with the regulatory framework, and PPC's documentation is thorough. However, the projection-dependent nature of the RAB percentages introduces inherent vulnerability, and the IRS will have the benefit of hindsight in evaluating the reasonableness of PPC's projections. We recommend that Whitmore prepare a comprehensive analysis demonstrating that PPC's projections were reasonable at the time they were made and that alternative projections — including those using actual results — do not materially alter the cost-sharing percentages.
B. Legacy IP Royalty Rate
1. PPC's Position
PPC's position is that the 4.5% royalty rate on legacy compound non-Americas net sales represents arm's-length compensation for PBI's use of PPC's intangible property, consistent with the standards of Treasury Regulation § 1.482-4. The royalty rate was established at the inception of the license agreement based on a comparable uncontrolled transaction ("CUT") analysis performed by Crestfield. The CUT analysis identified third-party pharmaceutical licensing agreements involving comparable intangible property, comparable therapeutic categories, and comparable market territories, and determined that the 4.5% royalty rate fell within the arm's-length range established by those comparable transactions.
Crestfield's contemporaneous transfer pricing documentation for each examination year reconfirms the arm's-length nature of the 4.5% royalty rate. The documentation includes the CUT analysis, a description of the comparable transactions used, and the methodology for selecting and adjusting those comparables. The CUT method was selected as the "best method" under Treasury Regulation § 1.482-1(c), based on the availability of reliable comparable data and the method's consistency with the guidance in Treasury Regulation § 1.482-4(c) for pricing intangible property transactions.
2. Potential IRS Challenge
The IRS is likely to assert that the 4.5% royalty rate substantially understates the arm's-length royalty for pharmaceutical IP of this nature and value. In recent transfer pricing examinations of pharmaceutical companies, the IRS has consistently challenged royalty rates in the 4%–6% range as below arm's length, proposing rates in the range of 10%–15% for pharmaceutical IP with characteristics similar to PPC's legacy compounds.
The IRS may conduct its own CUT analysis, selecting a different set of comparable third-party licensing agreements that yield higher royalty rates. Common points of dispute in CUT analyses include the comparability of the therapeutic category, the stage of product development, the size and scope of the licensed territory, the profit potential of the licensed products, and the presence or absence of exclusivity provisions, co-promotion rights, and milestone payments. The IRS may also argue that PPC's selected comparables are not sufficiently comparable to PPC's legacy compounds — for example, because PPC's comparables involve less valuable IP, smaller markets, or different risk profiles — and may substitute its own comparables that yield higher royalty rates.
Based on our review of recent IRS examination outcomes and litigated cases involving pharmaceutical royalty rates, we would expect the IRS to propose a royalty rate in the range of 9%–12%. At a proposed rate of 11%, the incremental royalty adjustment across all four examination years would approximate $186 million to $190 million, calculated as follows:
The declining legacy net sales base somewhat mitigates the exposure, as the incremental adjustment decreases in absolute terms over the four-year period. However, the aggregate exposure remains substantial.
3. Assessment of Defensibility
The CUT analysis will be a central battleground in this examination. The defensibility of PPC's 4.5% royalty rate depends critically on the comparability and quality of the CUT agreements used in Crestfield's analysis, and on PPC's ability to demonstrate that its selected comparables are more reliable and probative than any alternative comparables the IRS may identify.
CUT analyses are inherently fact-intensive, and comparability disputes are among the most common and contentious issues in transfer pricing litigation. The IRS will likely challenge the degree of comparability between PPC's selected transactions and the controlled transaction, focusing on differences in product characteristics, profit potential, geographic scope, and contractual terms. PPC must be prepared to defend the comparability of its CUT agreements through detailed adjustments and a rigorous comparability analysis.
C&H has directed Whitmore to conduct an independent CUT analysis, identifying comparable pharmaceutical license agreements from publicly available databases (including Vireo Health IT, Sundial Health IT, and SEC filings) and establishing the interquartile range ("IQR") for the arm's-length royalty rate. The goal of this analysis is to confirm that PPC's 4.5% rate falls within the IQR of reliable comparables, which would provide PPC with penalty protection under Treasury Regulation § 1.482-4(d)(2) and strengthen PPC's factual position in any dispute.
Defensibility Assessment: Moderate. CUT analyses are inherently vulnerable to IRS challenge, and comparability disputes are common. The pharmaceutical licensing landscape is highly heterogeneous, and it is possible that the IRS will identify comparables that support a higher royalty rate. However, if Whitmore can identify a robust set of comparables supporting an IQR that includes 4.5%, PPC's position should be sustainable, particularly if the comparables are drawn from transactions involving similar therapeutic categories, product lifecycle stages, and geographic scopes.
C. Platform Contribution Transaction Valuation
1. PPC's Position
On July 1, 2012, PBI made a lump-sum PCT payment of $312 million to PPC as consideration for a buy-in to PPC's pre-existing pharmaceutical IP portfolio for the non-Americas territory. The PCT was valued at the time of the transaction using an income method / Discounted cash flow ("DCF") approach, consistent with the methodologies prescribed in Treasury Regulation § 1.482-7(g)(4) for valuing platform contributions to qualified cost-sharing arrangements.
The DCF valuation reflected the expected future cash flows from PBI's exploitation of the contributed IP in the non-Americas territory, discounted to present value using a weighted average cost of capital ("WACC") determined to be appropriate for pharmaceutical IP of this nature and risk profile. The valuation was performed by Crestfield and documented in the contemporaneous transfer pricing report for Tax Year 2012.
2. Potential IRS Challenge
Although Tax Year 2012 falls outside the four-year examination window, the IRS may use a PCT undervaluation theory to challenge the ongoing CSA economics for Tax Years 2017–2020. This approach has been employed by the IRS in several recent examinations and litigated cases, and is based on the theory that an understated PCT payment creates a systemic distortion in the CSA that persists throughout the life of the arrangement.
Specifically, the IRS may argue that the $312 million PCT payment was substantially below the arm's-length value of the contributed IP, and that a higher PCT payment — potentially $800 million or more — would have been required to compensate PPC adequately for the pre-existing IP. The shortfall in the initial payment, the IRS may argue, effectively subsidized PBI's participation in the CSA and allowed PBI to retain a disproportionate share of the residual returns from the contributed IP during the examination years.
The IRS's income-method valuation may differ from PPC's in several respects, including the discount rate applied, the revenue and profit projections used, the growth assumptions, and the terminal value methodology. In particular, the IRS may argue that PPC used an overly high discount rate (which reduces the present value of future cash flows and thus reduces the PCT value), or that PPC's revenue projections at the time of the PCT underestimated the commercial potential of the contributed IP — particularly Veritaxol, which became a blockbuster product generating over $3 billion in annual global revenue by 2020.
3. Assessment of Defensibility
The PCT valuation will require a thorough re-examination using the data available at the time of the 2012 transaction, as well as an analysis of how the PCT valuation interacts with the ongoing CSA cost-sharing adjustments for the 2017–2020 period.
The key variables in the DCF analysis are the discount rate (WACC) applied and the revenue projections used. C&H has directed Whitmore to prepare an independent DCF analysis of the PCT using a defensible WACC and revenue projections that were reasonable as of July 1, 2012. Whitmore's preliminary view, based on an initial review of the underlying data, is that a WACC in the range of 9%–10% is appropriate for pharmaceutical IP of this type and risk profile — reflecting the inherent uncertainty in pharmaceutical product development, regulatory approval timelines, and market adoption rates. At a WACC in this range, Whitmore anticipates that its DCF analysis would support a PCT value range that brackets PPC's $312 million payment, thereby confirming that the PCT was within the arm's-length range.
It is critical to note that the reasonableness of the PCT valuation must be assessed based on the information available at the time of the transaction (July 2012), not with the benefit of hindsight regarding the subsequent commercial success of Veritaxol and other contributed compounds. The IRS has historically attempted to incorporate hindsight data into its PCT valuations, but this approach has been challenged successfully by taxpayers in several Tax Court cases, and the regulations require that the valuation be based on "the most reliable measure of an arm's length charge" at the time of the transaction.
The link between the PCT valuation and the ongoing CSA adjustments introduces additional complexity. If the IRS argues that the PCT was understated, it may attempt to recharacterize the ongoing CSA cost-sharing payments as including a deferred component of the PCT, which would increase the effective cost-sharing payments flowing from PBI to PPC. This argument would need to be addressed in conjunction with the CSA cost-sharing ratio analysis discussed in Section IV.A above.
Defensibility Assessment: Moderate to Strong on the PCT valuation itself, provided that PPC can demonstrate that the WACC and revenue projections used in the 2012 valuation were reasonable at the time. The connection between the PCT and the ongoing CSA adjustments adds complexity, but PPC's overall CSA framework is defensible if the PCT is shown to be within the arm's-length range.
D. PBI Economic Substance and DEMPE Functions
1. PPC's Position
PPC's position is that PBI has substantial economic substance in Ireland and performs key DEMPE functions that justify its role as the IP-holding company and CSA participant for the non-Americas territory. The factual evidence supporting PBI's substance and functional contributions includes the following:
• Personnel: PBI employed 185 individuals as of December 31, 2020, a significant increase from the 52 employees at the time of PBI's incorporation in March 2012. PBI's employees include experienced pharmaceutical professionals in regulatory affairs, medical affairs, commercial strategy, supply chain management, and finance.
• Management: PBI is led by Managing Director Aidan Naughton, who is resident in Ireland and exercises day-to-day management authority over PBI's operations.
• Governance: PBI's board of directors held 42 meetings during the 2017–2020 period — approximately quarterly plus additional special sessions — all of which were held in Dublin. The board meeting minutes reflect substantive deliberation on key commercial, regulatory, and strategic matters.
• Office Facilities: PBI maintains approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, which houses PBI's operational teams and management.
• Regulatory Expenditures: PBI incurred cumulative regulatory expenditures of approximately €47.2 million during the 2017–2020 period on regulatory submissions and post-approval activities in non-Americas markets.
• Commercial Decision-Making: PBI makes independent pricing decisions across 68 country markets, selects and manages distribution partners, determines market entry sequencing, and develops commercial strategies tailored to local market conditions in the EMEA and Asia-Pacific regions.
• Local Banking: PBI maintains its primary banking relationship with Glenmore Bank Ireland plc and manages its treasury functions locally in Dublin.
With respect to the specific DEMPE functions, PPC's position is as follows:
• Development: Development functions are shared through the CSA, with PBI co-funding R&D proportionate to its RAB share. While the majority of laboratory-based R&D is conducted at PPC's U.S. facilities, PBI's contribution to the cost of development constitutes meaningful participation in the development function.
• Enhancement: PBI performs Enhancement functions, including local formulation adaptations to meet regional regulatory requirements, clinical data package modifications for non-Americas regulatory submissions, and post-approval studies and label extensions in PBI's territory.
• Maintenance: PBI performs Maintenance functions, including pharmacovigilance, quality oversight of contract manufacturing operations (through PMI and third-party manufacturers), and ongoing regulatory compliance in non-Americas markets.
• Protection: PBI is responsible for the registration and enforcement of PPC's IP rights in non-Americas jurisdictions, including patent filings, trademark registrations, and coordination of anti-counterfeiting efforts.
• Exploitation: PBI performs the full range of Exploitation functions in its territory, including commercialization, distribution partner management, pricing, reimbursement negotiations, medical education, and promotional activities across 68 country markets.
2. Potential IRS Challenge
The IRS may argue that PBI's claimed substance and functional contributions are insufficient to justify its role as IP owner and CSA participant, and that the critical Development and Enhancement functions — particularly core R&D, clinical trials management, and strategic IP portfolio decisions — remained in the United States under PPC's control throughout the examination period.
The IRS's argument may take one or more of the following forms:
(a) "Cash box" Characterization. The IRS may characterize PBI as a "cash box" or limited-function entity — an entity that holds IP rights on paper and receives substantial income, but lacks the personnel, expertise, and decision-making authority to justify its role as IP owner. Under this characterization, PBI would be treated as, at most, a contract distributor or limited-risk licensee entitled to a routine return, with the residual returns attributed to PPC in the United States.
(b) Control of Key Functions. The IRS may argue that PPC's U.S.-based R&D team exercised de facto control over all material intangible development activities, including the selection of R&D priorities, the design of clinical trials, the interpretation of clinical data, and the strategic decisions regarding IP portfolio management. If the IRS can establish that these functions were controlled from the U.S., it would undermine the premise that PBI's cost-sharing payments entitle it to a share of the residual returns from the resulting IP.
(c) Personnel-Based Analysis. The IRS may conduct a personnel-based analysis comparing the number, seniority, and functional responsibilities of PPC's U.S.-based R&D and commercial personnel against PBI's 185 Dublin-based employees. To the extent that PPC's U.S. operations employ a substantially larger number of R&D professionals and senior decision-makers, the IRS may argue that the balance of functions and decision-making authority is weighted toward the United States.
If the IRS succeeds in establishing that PBI lacks sufficient substance or fails to perform adequate DEMPE functions, this finding would support both the CSA and royalty adjustments by undermining the premise that PBI is entitled to the residual returns it currently earns from non-Americas exploitation.
3. Assessment of Defensibility
This is an area where PPC has strong factual defenses, but the evidence must be carefully marshaled and presented. The growth in PBI's headcount from 52 employees at incorporation to 185 employees by 2020 demonstrates a substantial and sustained investment in building operational capabilities in Ireland. The 42 board meetings held in Dublin during the four-year examination period, the €47.2 million in cumulative regulatory expenditures, and the demonstrated independence in commercial decisions across 68 country markets are all powerful evidence of genuine economic substance and functional contributions.
However, the IRS will likely attempt to look beyond the surface-level headcount and governance metrics to probe the quality and independence of PBI's decision-making. The IRS may seek to establish that PBI's board meetings were largely pro forma, that key decisions were effectively pre-determined by PPC's U.S. management, or that PBI's commercial strategy was dictated by PPC's global commercial leadership rather than independently developed in Dublin. These allegations can be rebutted with a thorough factual record, but the rebuttal must be grounded in specific, documented evidence of independent PBI decision-making.
C&H will prepare a comprehensive functional analysis documenting PBI's activities, personnel, decision-making processes, and risk management functions during the 2017–2020 period. This analysis will include:
• Interviews of 12 key PBI employees in Dublin, conducted by C&H attorneys (Simmons and Nazari) at PBI's offices, to document each employee's role, responsibilities, decision-making authority, and functional contributions.
• A detailed analysis of all 42 PBI board meetings (2017–2020), including a review of board minutes, board presentations, and board resolutions, to document the scope and substance of the board's deliberations and the independence of its decision-making.
• A DEMPE functions matrix allocating specific DEMPE functions between PPC and PBI for each product line (Veritaxol, Imvara, Cerulon, and legacy compounds), with supporting evidence drawn from organizational charts, job descriptions, internal communications, and decision memoranda.
Defensibility Assessment: Strong, provided we can thoroughly document PBI's functions and present the evidence persuasively. The factual record supports PBI's substance, and the IRS's "cash box" characterization should be refutable given the scope of PBI's operations. The key risk is that PBI's decision-making may be perceived as derivative of or subordinate to PPC's global strategy, and this perception must be addressed head-on through careful documentation of PBI's independent contributions.
V. Preliminary Exposure Quantification
A. Potential Adjustment Ranges
Based on C&H's experience with similar IRS transfer pricing examinations of pharmaceutical companies and our preliminary analysis of PPC's positions, we estimate the following potential adjustment ranges for the four examination years:
CSA Cost-Sharing Adjustments. If the IRS proposes increasing PBI's cost-sharing percentage by approximately 10 percentage points per year — from PPC's reported percentages of 38.2%–42.7% to IRS-proposed percentages of approximately 48%–53% — the incremental cost-sharing payments that would flow from PBI to PPC could total approximately $230 million to $240 million across all four examination years. The specific calculation for each year is as follows:
Royalty Rate Adjustments. If the IRS proposes a royalty rate of 10%–12% (compared to PPC's 4.5%), the incremental royalties that would flow from PBI to PPC could total approximately $160 million to $210 million across all four examination years, as detailed in Section IV.B.2 above.
Correlative Offsets. Any adjustments to both the CSA cost-sharing payments and the legacy IP royalty rate would need to account for overlap and correlative effects. To the extent that both adjustments are premised on the theory that PPC contributed more value than was reflected in the existing arrangements, there is a risk of double-counting the same income. Correlative adjustments or offsets could reduce the net adjustment by approximately $30 million to $50 million. The specific correlative analysis will depend on the IRS's articulation of its adjustments and the interaction between the CSA and royalty theories.
Preliminary Net Exposure Range. Combining the CSA and royalty adjustments and accounting for correlative offsets, we estimate a preliminary net exposure range of approximately $340 million to $400 million in proposed Section 482 adjustments across all four examination years. This represents the aggregate increase in PPC's U.S.-source taxable income that the IRS may propose.
B. Tax and Penalty Implications
Federal Income Tax. At a 21% federal corporate income tax rate — applicable to Tax Years 2018, 2019, and 2020 — a proposed adjustment of $380 million (the midpoint of our estimated range) would generate approximately $80 million in proposed additional federal income tax. For Tax Year 2017, the applicable rate is a blended rate reflecting the 35% rate in effect prior to the Tax Cuts and Jobs Act ("TCJA") and the 21% rate effective for taxable years beginning after January 1, 2018. The specific computation for TY 2017 will depend on PPC's fiscal year-end and the mechanics of the blended rate calculation, but the effective rate for TY 2017 is likely in the range of 26%–28%.
Substantial Valuation Misstatement Penalty. The IRS may assert the IRC § 6662(e) substantial valuation misstatement penalty at a rate of 20% on the net Section 482 allocation. For a proposed adjustment of $380 million generating approximately $80 million in additional tax, the 20% penalty could add approximately $16 million. The IRS may also reserve the right to assert the IRC § 6662(h) gross valuation misstatement penalty at a rate of 40%, although based on our assessment of PPC's documentation, we do not believe the IRS would have a strong basis for asserting the 40% penalty. PPC's contemporaneous transfer pricing documentation, prepared by Crestfield in accordance with the penalty-protection standards of IRC § 6662(e)(3)(B), should provide a reasonable-cause defense against the penalty, though the strength of this defense will depend on the quality and completeness of the documentation and the extent to which it supports PPC's specific transfer pricing positions.
Interest. Interest on any underpayment would accrue at the applicable federal underpayment rate (currently the federal short-term rate plus 3 percentage points, compounded daily) from the original due dates of the returns for each examination year through the date of payment. Given the multi-year span of the examination, the interest accumulation could be significant, though a precise calculation is not possible until the timing and amount of any settlement or assessed deficiency is known.
Total Preliminary Worst-Case Exposure. Based on the foregoing analysis, PPC's total preliminary worst-case exposure is estimated at approximately:
• Federal income tax: approximately $80 million
• Section 6662(e) penalty (20%): approximately $16 million
• Interest: to be determined (dependent on timing of resolution)
• Total: approximately $96 million+ before interest
We emphasize that this is a worst-case estimate based on the upper end of the potential adjustment range and the assumption that the IRS prevails on all issues. In practice, the actual exposure is likely to be substantially lower if PPC's defense is effective, and particularly if the case is resolved through IRS Appeals on a hazards-of-litigation basis.
C. Interaction with GILTI and BEAT
For Tax Years 2018, 2019, and 2020, any Section 482 adjustment that increases PPC's U.S.-source income and correspondingly reduces PBI's income could interact with PPC's Global Intangible Low-Taxed Income ("GILTI") position under IRC § 951A and its Base Erosion and Anti-Abuse Tax ("BEAT") position under IRC § 59A.
Under GILTI, PPC is required to include in its U.S. taxable income its pro rata share of PBI's "tested income" (net of the deemed tangible income return). A reduction in PBI's income as a result of a Section 482 adjustment would reduce PPC's GILTI inclusion, which would partially offset the increase in PPC's U.S.-source income from the Section 482 adjustment itself. The net tax effect of the Section 482 adjustment must therefore be computed on an after-GILTI basis.
Similarly, a Section 482 adjustment that reduces intercompany payments from PPC to PBI (or increases payments fr

MEMORANDUM

Record

Parties

Dates

Amounts